We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
e-Therapeutics Appoints Daniel Elger as Chief Financial Officer
News

e-Therapeutics Appoints Daniel Elger as Chief Financial Officer

e-Therapeutics Appoints Daniel Elger as Chief Financial Officer
News

e-Therapeutics Appoints Daniel Elger as Chief Financial Officer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "e-Therapeutics Appoints Daniel Elger as Chief Financial Officer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

e-Therapeutics plc has announced that Dr Daniel Elger will be joining the Company and its Board as Chief Financial Officer, with immediate effect.

Dr Elger, 41, was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc. He joined that company in 2002 and served on its Senior Management Team from 2005, playing significant roles in corporate strategy, fundraisings and the acquisition of two US biotech companies.

He also directed the investor relations strategy for the Company. Before Antisoma, Daniel was a Programme Director for major pharmaceutical companies at a leading marketing and communications agency. He holds a BA in Physiological Sciences (Medicine) and a PhD in cancer cell biology, both from Oxford University.

Malcolm Young, e-Therapeutics Chief Executive said, “Daniel has a wide set of skills across corporate, financial and communications areas, and he is a valuable addition to the e-Therapeutics team. Following our £21m placing at the beginning of the year, implementing our strategic plans and communicating them to current and potential shareholders will be key elements of his role. We look forward to working with him.”

There is no other information that is required to be disclosed with regards to the above mentioned appointment pursuant to Schedule 2 paragraph (g) of the AIM Rules.

We announce the departure of Mr J.M. Cordiner from his position as Finance Director of e-Therapeutics plc and from the Board on 10 June 2011 in order to pursue other business interests. Oliver James, Non-Executive Chairman of e-Therapeutics said: "e-Therapeutics thanks Johnny for his services and wishes him well in his new business ventures."

Advertisement